There are 412 resources available
The current and future treatment landscape for ER+/HER2- metastatic breast cancer setting
Presenter: Renate Haidinger
Session: Pfizer - Tailoring journeys: Customised care with CDK4/6 inhibitors in HR+ HER2- metastatic breast cancer
Resources:
Webcast
An encompassing journey: Shaping clinical decisions
Presenter: Richard Finn
Session: Pfizer - Tailoring journeys: Customised care with CDK4/6 inhibitors in HR+ HER2- metastatic breast cancer
Resources:
Webcast
A unique journey: Personalising approaches
Presenter: Antonio LLOMBART CUSSAC
Session: Pfizer - Tailoring journeys: Customised care with CDK4/6 inhibitors in HR+ HER2- metastatic breast cancer
Resources:
Webcast
Panel discussion and audience Q&A
Session: Pfizer - Tailoring journeys: Customised care with CDK4/6 inhibitors in HR+ HER2- metastatic breast cancer
Resources:
Webcast
Closing remarks
Presenter: Richard Finn
Session: Pfizer - Tailoring journeys: Customised care with CDK4/6 inhibitors in HR+ HER2- metastatic breast cancer
Resources:
Webcast
182MO - Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2+ metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1): Updated overall survival (OS) results of the randomized phase III DESTINY-breast (DB-)02 study
Presenter: Sung-Bae Kim
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
New promising targets beyond HER2 and TROP2
Presenter: Erika Hamilton
Session: New ADCs joining the field
Resources:
Slides
Webcast
267MO - Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment (RTx) after recovery from grade (Gr) 1 interstitial lung disease/pneumonitis (ILD)
Presenter: Hope Rugo
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Combination strategies: Focus on ADCs and IO-based strategies
Presenter: Rebecca Dent
Session: New ADCs joining the field
Resources:
Slides
Webcast
LBA3 - SOLTI-1507 IPATHER: Primary results of the phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with trastuzumab and pertuzumab (HP) in patients (pts) with PIK3CA mutant (mut) HER2+ advanced breast cancer (ABC)
Presenter: Ana Mafalda Antunes De Melo e Oliveira
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast